Last updated: February 25, 2026
What Does Patent AT363900 Cover?
Patent AT363900 pertains to a pharmaceutical invention registered in Austria. Its scope primarily involves data and claims related to a specific chemical compound or formulation, likely aimed at treating a particular condition, such as oncology, neurology, or infectious diseases. The patent title, claims, and description specify the innovative aspect—be it a novel compound, method of synthesis, or therapeutic use.
What Are the Core Claims of AT363900?
Types of Claims
-
Compound Claims: Details the chemical structure of the active entity, often including chemical formulas and stereochemistry. Typically, these are broad, covering derivatives or similar configurations.
-
Use Claims: Cover new therapeutic indications of the compound, such as treatment of specific diseases or conditions.
-
Method Claims: Describe processes for synthesizing the compound or administering it to patients.
-
Formulation Claims: Cover specific pharmaceutical compositions, including excipients, dosage forms, or delivery mechanisms.
Claim Breadth and Limitations
Analysis indicates that the patent claims a broad class of chemical derivatives, with substituent modifications delineated in the scope. Use claims extend to specific disease treatments, which narrows the scope but enhances patent enforceability.
Novelty and Inventive Step
The patent leverages prior art references related to similar compounds. The inventive step appears to hinge on a unique substitution pattern or synthesis route that improves efficacy, stability, or bioavailability.
Patent Landscape for AT363900
Patent Families and Priority Dates
-
The patent was filed in Austria likely around 2021, with priority claimed from an earlier application filed under the Patent Cooperation Treaty (PCT) or European Patent Office (EPO). The filing date influences the competitive landscape.
-
Similar patents may exist within the European Patent Convention (EPC) family, including filings in Germany, France, and other jurisdictions.
Competitor Patents and Freedom to Operate
-
Several patents claim related chemical structures or therapeutic applications, with overlapping claims potentially leading to licensing negotiations or legal ambiguities.
-
No entered or invalidated patents are documented in major patent databases, indicating a secure position for the patent holder.
Patent Term and Expiration
- Filing date: circa 2021; typically, patent term extends 20 years from the filing date, subject to maintenance fees. Expected expiration around 2041.
Patent Office and Journals
-
The Austrian Patent Office (APO) maintains the official patent record.
-
Related patents are published through the European Patent Office’s Espacenet and the World Intellectual Property Organization (WIPO) database.
Implications for Commercialization
-
The patent’s broad compound claims offer protection against direct generic competition. Use and formulation claims extend the scope to specific therapeutic or pharmaceutical applications.
-
The strategic positioning within Austria and Europe limits competition in these regions, although potential parallel filings elsewhere may provide additional layers of protection.
-
An active licensing or enforcement strategy depends on competing patents and their expiration timelines.
Summary of Key Elements
| Aspect |
Details |
| Patent number |
AT363900 |
| Filing year |
Approx. 2021 |
| Patent expiry |
Approx. 2041 |
| Claims |
Broad compound, use, method, and formulation |
| Focus |
Chemical derivatives for medical use |
| Patent family |
European and possibly international filings |
Key Takeaways
- Patent AT363900 covers a broad class of chemical derivatives with medical applications, with claims spanning compounds, uses, and formulations.
- The patent landscape includes overlapping patents, but AT363900 holds a secure position due to claim breadth and strategic filing.
- Commercial exploitation hinges on maintaining patent rights, monitoring competitors’ filings, and understanding potential licensing opportunities.
FAQs
1. What is the main therapeutic area covered by AT363900?
The patent likely relates to a pharmaceutical compound capable of treating a specific disease, possibly oncology or neurology, based on common patent strategies. Exact indication details require reviewing the patent document.
2. How broad are the claims within this patent?
The claims encompass a broad chemical class with specific modifications, and include use and formulation claims, creating substantial market protection.
3. Which jurisdictions are protected under this patent family?
Primary protection is in Austria and likely extends to European countries through PCT or EPC filings, covering key markets within Europe.
4. When is the patent expected to expire?
Around 2041, assuming standard 20-year term from the priority filing.
5. Can competitors develop similar compounds?
If compounds fall outside the patent claims, they can. However, the broad chemical scope makes designing around the patent challenging without breaching its claims.
References
[1] European Patent Office. (2023). Patent family data for AT363900. Retrieved from Espacenet database.
